Retrospective study assessing if established threshold concentrations of infliximab (IFX), adalimumab (ADA), and ustekinumab (UST) impact outcomes in POCD
Latest Information Update: 14 Dec 2022
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
Most Recent Events
- 14 Dec 2022 New trial record
- 01 Dec 2022 Results published in the Inflammatory Bowel Diseases